DICE Therapeutics Inc IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| DICE Therapeutics Inc | DICE - NASDAQ |
$15.00-$17.00 | $17.00 | $30.00 | 12 million | 9/15/2021 |
| BofA Securities, SVB Leerink, Evercore ISI | ||||||
Co-Manager(s): | ||||||
Filing(s): Filed 2021-08-25 Terms Added 2021-09-09 | ||||||
DICE Therapeutics Inc Quote & Chart - Click for current quote - DICE
IPO Boutique aggregates information on public companies and private companies, such as "DICE" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About DICE Therapeutics Inc (adapted from DICE Therapeutics Inc prospectus):
They are a biopharmaceutical company leveraging our proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a biopharmaceutical company leveraging our proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "DICE" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.